BioNexus Gene Lab Corp Common stock (BGLC) — Capital Reinvestment Ratio
BioNexus Gene Lab Corp Common stock (BGLC) has a Capital Reinvestment Ratio of 0.04x as of December 2022, meaning it reinvests 0% of its operating cash flow ($474.47K) in capital expenditures ($17.03K). See BioNexus Gene Lab Corp Common stock balance sheet independence to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
BioNexus Gene Lab Corp Common stock Capital Reinvestment Ratio (2017–2022)
This chart tracks BioNexus Gene Lab Corp Common stock's Capital Reinvestment Ratio across 4 annual periods. Check BGLC capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for BioNexus Gene Lab Corp Common stock (2017–2022)
Year-by-year Capital Reinvestment Ratio for BioNexus Gene Lab Corp Common stock from 2017 to 2022. For live market cap and broader valuation context, see BGLC market cap.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.10x | $544.03K | $54.17K | ▼ -71.2% |
| 2021 | 0.35x | $9.16K | $3.16K | ▼ -54.8% |
| 2020 | 0.76x | $552.68K | $421.62K | ▼ -13.4% |
| 2017 | 0.88x | $357.22K | $314.82K | — |